

Supplement to:

Phase-3 Dose Selection of Marzeptacog Alfa (Activated) Informed by Population
Pharmacokinetic Modeling: A Novel Hemostatic Drug

Alan Faraj¹, Tom Knudsen², Shraddha Desai², Linda Neuman², Grant E. Blouse², Ulrika S.H.
Simonsson^{1*}

Affiliations:

¹Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

²Catalyst Biosciences, South San Francisco, CA, USA




Figure S1. Pred-corrected visual predictive check of the final population PK model on log scale following SC and IV dosing. The SC pcVPC is limited to time since last dose of 48 hours for simplicity but 19 observations between 48-80 hours are included and falls within the last bin that is visible at time 48h. The solid and dashed lines are the median and, 2.5th and 97.5th percentiles of the observed data, respectively. The shaded areas (top to bottom) are the 95% confidence intervals of the 97.5th (light grey), median (dark grey) and 2.5th (light grey) percentiles of the simulated data. Open circles are prediction-corrected observation points.